TG Therapeutics, Inc. (TGTX) Stock Forecast
Data as of Oct 31, 2026Healthcare · Current price $60.76 (+4.61%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Oct 6, 2025 | Emily Bodnar | H.C. Wainwright | $60.00 | -1.3% |
| Nov 5, 2024 | Edward White | H.C. Wainwright | $27.50 | -54.7% |
| Aug 6, 2024 | Corinne Jenkins | Goldman Sachs | $20.00 | -67.1% |
| May 3, 2024 | Edward White | H.C. Wainwright | $24.50 | -59.7% |
| Dec 29, 2022 | Edward White | H.C. Wainwright | $12.00 | -80.3% |
| Apr 18, 2022 | Mayank Mamtani | Telsey Advisory | $11.50 | -81.1% |
Top Analysts Covering TGTX
TGTX vs Sector & Market
| Metric | TGTX | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.25 | 2.25 | 2.41 |
| Analyst Count | 8 | 8 | 19 |
| Target Upside | +32.5% | +153002.0% | +21.5% |
| P/E Ratio | 21.24 | 3.45 | 38.49 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $245M | $251M | $256M | 2 |
| 2027-12-31 | $1.09B | $1.15B | $1.21B | 5 |
| 2028-12-31 | $1.38B | $1.46B | $1.52B | 4 |
| 2029-12-31 | $1.67B | $1.76B | $1.84B | 3 |
| 2030-12-31 | $1.93B | $2.04B | $2.13B | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $0.40 | $0.41 | $0.42 | 2 |
| 2027-12-31 | $1.44 | $2.20 | $2.78 | 4 |
| 2028-12-31 | $1.96 | $2.78 | $3.80 | 4 |
| 2029-12-31 | $2.92 | $3.14 | $3.31 | 2 |
| 2030-12-31 | $3.57 | $3.84 | $4.05 | 2 |
Frequently Asked Questions
What is the analyst consensus for TGTX?
The consensus among 8 analysts covering TG Therapeutics, Inc. (TGTX) is Buy with an average price target of $80.50.
What is the highest price target for TGTX?
The highest price target for TGTX is $60.00, set by Emily Bodnar at H.C. Wainwright on 2025-10-06.
What is the lowest price target for TGTX?
The lowest price target for TGTX is $11.50, set by Mayank Mamtani at Telsey Advisory on 2022-04-18.
How many analysts cover TGTX?
8 analysts have issued ratings for TG Therapeutics, Inc. in the past 12 months.
Is TGTX a buy or sell right now?
Based on 8 analyst ratings, TGTX has a consensus rating of Buy (2.25/5) with a +32.5% upside to the consensus target of $80.50.
What are the earnings estimates for TGTX?
Analysts estimate TGTX will report EPS of $0.41 for the period ending 2026-12-31, with revenue estimated at $251M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.